Indivior Pharmaceuticals, Inc. INDV Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Indivior Pharmaceuticals, Inc. 's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Indivior Pharmaceuticals, Inc. 's accrued expenses?
- Indivior Pharmaceuticals, Inc. (INDV) reported accrued expenses of $42M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc. 's accrued expenses changed year-over-year?
- Indivior Pharmaceuticals, Inc. 's accrued expenses decreased by 6.7% year-over-year, from $45M to $42M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc. 's accrued expenses?
- Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc. 's accrued expenses has grown at a 60.5% compound annual growth rate (CAGR), from $40M to $103M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.